The dopaminergic system mediates motor control, motivation, reward, prolactin regulation, and aspects of cognition. In neurology, dopaminergic pharmacology is central to Parkinson disease management, restless legs syndrome, prolactinoma, hyperprolactinemia from antipsychotics, and the spectrum of dopamine-modulating drugs used in psychiatry. This page covers the four major dopaminergic pathways, receptor pharmacology, and therapeutic and toxicological dopaminergic drugs.

Dopaminergic Anatomy: Four Pathways

  • Nigrostriatal: substantia nigra pars compacta → striatum; motor control. Degenerates in PD.
  • Mesolimbic: VTA → nucleus accumbens, amygdala; reward, motivation, addiction.
  • Mesocortical: VTA → prefrontal cortex; cognition, executive function, motivation.
  • Tuberoinfundibular: arcuate nucleus → median eminence; suppresses prolactin release.

Dopamine Receptors

D1-like Family (D1, D5)

  • Gs-coupled → increase cAMP.
  • D1: striatum (direct pathway); cortex; reward.
  • D5: hippocampus, cortex.
  • Postsynaptic, excitatory.

D2-like Family (D2, D3, D4)

  • Gi-coupled → decrease cAMP.
  • D2: striatum (indirect pathway), VTA presynaptic autoreceptor; pituitary (prolactin); chemoreceptor trigger zone (nausea). Target of antipsychotics (block) and dopamine agonists (stimulate).
  • D3: limbic, nucleus accumbens; addiction, reward.
  • D4: frontal cortex, limbic; ADHD, atypical antipsychotics.

Dopamine Synthesis and Metabolism

  • Tyrosine → DOPA (tyrosine hydroxylase, rate-limiting) → dopamine (DOPA decarboxylase).
  • Storage: VMAT2 (vesicular monoamine transporter).
  • Release: Ca²⁺-dependent.
  • Reuptake: dopamine transporter (DAT).
  • Metabolism: MAO-B (preferential), MAO-A, COMT → homovanillic acid (HVA).

Major Drug Classes

Levodopa

  • Dopamine precursor; converted to dopamine by aromatic amino acid decarboxylase (AAAD).
  • Crosses BBB (dopamine does not).
  • Co-administered with carbidopa or benserazide (AAAD inhibitors that do not cross BBB) to prevent peripheral conversion → less nausea, more brain delivery.
  • Most effective PD treatment.
  • Complications: motor fluctuations (“on-off”), dyskinesias, psychosis, sleep, impulse control disorders, freezing.
  • Levodopa-carbidopa intestinal gel (continuous duodenal infusion) for advanced PD.
  • Foslevodopa: SC continuous infusion (Vyalev).
  • Inhaled levodopa (Inbrija): rescue for “off” episodes.

Dopamine Agonists

  • Pramipexole: D2/D3 selective; PD, restless legs.
  • Ropinirole: similar to pramipexole.
  • Rotigotine: transdermal patch; D2/D3.
  • Apomorphine: SC rescue for severe “off” episodes; oral sublingual form (Kynmobi).
  • Bromocriptine, cabergoline: ergot derivatives; PD, prolactinoma; cabergoline preferred for prolactinoma.
  • Side effects: nausea, orthostasis, sleepiness (“sleep attacks”), impulse control disorders (gambling, hypersexuality, binge eating, compulsive shopping — counsel patient + family), valvular heart disease (ergot agonists).

MAO-B Inhibitors

  • Selegiline: irreversible MAO-B inhibitor; PD (especially early); transdermal patch (for depression — higher dose, less selective).
  • Rasagiline: irreversible MAO-B inhibitor; PD; possible disease-modifying signal (debated).
  • Safinamide: MAO-B inhibitor + glutamate modulator; for “off” episodes in PD.
  • Less stringent dietary restrictions than nonselective MAOIs at typical doses; can have serotonin syndrome with SSRI co-administration.

COMT Inhibitors

  • Entacapone: peripheral COMT inhibitor; reduces peripheral levodopa metabolism, extends “on” time; combination tablet with carbidopa-levodopa (Stalevo).
  • Opicapone: once-daily peripheral COMT inhibitor; for motor fluctuations.
  • Tolcapone: central + peripheral COMT inhibitor; hepatotoxicity risk; restricted use.

Amantadine

  • Increases dopamine release, NMDA antagonist.
  • For PD: dyskinesias (mainstay).
  • Once used for influenza A (rarely now).
  • Side effects: livedo reticularis, hallucinations, peripheral edema.

Anticholinergics for PD

  • Benztropine, trihexyphenidyl: for tremor and drug-induced parkinsonism; less effective for bradykinesia.
  • Cognitive side effects → avoid in elderly.

Antipsychotics (D2 Antagonists)

  • Typical (1st gen): haloperidol, chlorpromazine, fluphenazine — strong D2 blockade; high parkinsonism, tardive dyskinesia, NMS risk.
  • Atypical (2nd gen): olanzapine, risperidone, quetiapine, aripiprazole (partial D2 agonist), clozapine — more 5-HT2 blockade, less D2; lower EPS but metabolic syndrome.
  • Clozapine: gold standard for treatment-resistant psychosis; lowest tardive dyskinesia; agranulocytosis (REMS monitoring).
  • Pimavanserin: selective 5-HT2A inverse agonist (no D2 blockade); for PD psychosis; does not worsen motor symptoms.
  • Side effects: parkinsonism, dystonia, akathisia, tardive dyskinesia, NMS, hyperprolactinemia, metabolic syndrome, cardiac arrhythmia (QT prolongation), sedation, anticholinergic.

VMAT2 Inhibitors

  • Tetrabenazine: depletes presynaptic dopamine; Huntington chorea, tardive dyskinesia.
  • Deutetrabenazine: deuterated; longer half-life; less frequent dosing.
  • Valbenazine: prodrug of active tetrabenazine metabolite; FDA-approved for tardive dyskinesia.
  • Side effects: depression, parkinsonism, sedation, akathisia.

Dopamine Antagonists for Nausea

  • Prochlorperazine, metoclopramide, promethazine, droperidol: D2 blockade in chemoreceptor trigger zone.
  • Side effects: EPS, akathisia, sedation, tardive dyskinesia, NMS.
  • Avoid in PD.
  • Alternatives in PD: ondansetron (5-HT3 antagonist) for nausea.

Stimulants (Indirect DA Agonists)

  • Methylphenidate, amphetamine derivatives: increase synaptic dopamine and norepinephrine.
  • ADHD, narcolepsy.

Clinical Applications

Parkinson Disease

  • Levodopa-carbidopa: gold standard.
  • MAO-B inhibitors: early PD, motor fluctuations.
  • Dopamine agonists: alternative early PD; “off” rescue (apomorphine, levodopa inhaler).
  • COMT inhibitors: motor fluctuations.
  • Amantadine: dyskinesias.
  • Anticholinergics: tremor (in younger patients).
  • DBS (subthalamic, GPi): advanced PD with motor fluctuations.
  • Focused ultrasound thalamotomy: alternative for tremor.

Restless Legs Syndrome

  • Treat iron deficiency first (ferritin <75-100 μg/L).
  • α2δ ligands (gabapentin, pregabalin) — first line for symptomatic relief in many guidelines.
  • Dopamine agonists (pramipexole, ropinirole, rotigotine) — effective but augmentation risk with long-term use; reserve for refractory.
  • Opioids in severe refractory.

Huntington Disease (Chorea)

  • Tetrabenazine, deutetrabenazine (VMAT2 inhibitors); reduce chorea.
  • Risperidone, olanzapine for chorea + behavioral symptoms.

Schizophrenia

  • Antipsychotics: D2 blockade central mechanism.
  • Second-generation preferred for first-episode psychosis.
  • Clozapine for treatment-resistant.

Tardive Dyskinesia

  • Long-term D2 blockade complication.
  • Treatment: VMAT2 inhibitors (valbenazine, deutetrabenazine).
  • Prevention: minimize antipsychotic exposure; prefer atypicals.

Prolactinoma

  • D2 agonists (cabergoline preferred): suppress prolactin, shrink tumor.

Neuroleptic Malignant Syndrome

  • Sudden D2 blockade or dopaminergic withdrawal.
  • Hyperthermia, rigidity, autonomic instability, altered mental status.
  • Treatment: discontinue D2 antagonist, supportive care, dantrolene, bromocriptine if severe.

🔍 Did You Know?

Impulse control disorders (ICDs) in Parkinson disease patients on dopamine agonists are one of the most clinically significant and underrecognized complications in modern PD management. Approximately 14-17% of PD patients treated with dopamine agonists (pramipexole, ropinirole, rotigotine, apomorphine) develop ICDs, which can include pathological gambling, hypersexuality, compulsive shopping, binge eating, hoarding, or compulsive medication use (dopamine dysregulation syndrome). These behaviors are often hidden by the patient (shame, denial) and may not surface until significant financial, marital, or legal consequences develop. The mechanism involves enhanced mesolimbic dopaminergic stimulation — the very pathway that drives reward and motivation — and individual susceptibility likely involves baseline impulsive personality traits, younger age, male sex, family history of addiction, and dopamine D3 receptor preference. The clinical implication is profound: every patient and family member should be counseled before starting dopamine agonists, and screened regularly during treatment. Specific screening: ask about gambling, sexual behavior changes, shopping, eating, secret behaviors — and ask the spouse/partner who often sees what the patient denies. Reducing or discontinuing the dopamine agonist (often with levodopa substitution) typically resolves the ICD, though some patients have persistent symptoms. The lesson generalizes: dopaminergic drugs alter not just motor function but motivation and reward processing, and the cost-benefit calculation in choosing therapies should explicitly include behavioral risks.

Pitfalls and Pearls

  • Four DA pathways: nigrostriatal (motor), mesolimbic (reward), mesocortical (cognition), tuberoinfundibular (prolactin).
  • D1-like (D1, D5): Gs-coupled, excitatory.
  • D2-like (D2, D3, D4): Gi-coupled, inhibitory; antipsychotic targets.
  • Levodopa + carbidopa: gold standard PD; carbidopa prevents peripheral conversion.
  • Motor fluctuations: levodopa “wearing off,” “on-off”; manage with COMT inhibitors, MAO-B inhibitors, dose adjustments, foslevodopa SC infusion, levodopa-carbidopa intestinal gel.
  • Dyskinesias: amantadine first-line; reduce levodopa peaks.
  • Dopamine agonists: pramipexole, ropinirole, rotigotine, apomorphine; warning about impulse control disorders and sleep attacks.
  • MAO-B inhibitors: selegiline, rasagiline, safinamide; selectivity at usual doses (less tyramine risk).
  • COMT inhibitors: entacapone, opicapone; tolcapone restricted (hepatotoxicity).
  • Pimavanserin: 5-HT2A inverse agonist; PD psychosis without worsening motor.
  • VMAT2 inhibitors: tetrabenazine, deutetrabenazine, valbenazine; chorea (HD) and tardive dyskinesia.
  • Avoid metoclopramide, prochlorperazine in PD: D2 blockade worsens motor symptoms.
  • Ondansetron in PD: safer for nausea.
  • Clozapine: best for treatment-resistant psychosis; agranulocytosis risk; REMS monitoring.
  • Tardive dyskinesia: prevention more important than treatment.
  • NMS: D2 blockade or sudden dopaminergic withdrawal; emergency.

References

  1. Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670-1683.
  2. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet. 2021;397(10291):2284-2303.
  3. Voon V, Napier TC, Frank MJ, et al. Impulse control disorders and levodopa-induced dyskinesias in Parkinson’s disease: an update. Lancet Neurol. 2017;16(3):238-250.
  4. Garcia-Borreguero D, Silber MH, Winkelman JW, et al. Guidelines for the first-line treatment of restless legs syndrome/Willis-Ekbom disease, prevention and treatment of dopaminergic augmentation. Sleep Med. 2016;21:1-11.
  5. Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am. 1993;77(1):185-202.
  6. Brunton LL, Hilal-Dandan R, Knollmann BC, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 14th ed. McGraw-Hill; 2023.